Teva-Pregabalin

Teva-Pregabalin appears to be a product brand name in the form used for generic pharmaceuticals, combining the manufacturer name (Teva) with the active ingredient (pregabalin). Pregabalin is a medication used in the treatment of neuropathic pain, epilepsy and generalized anxiety disorder, and generic versions are marketed by many manufacturers under ingredient-based brand names of this type. On that reading, Teva-Pregabalin would be a generic prescription medicine brand belonging to Teva Pharmaceutical Industries, an Israeli-headquartered multinational pharmaceutical company. However, the evidence supplied for this entry does not support any of these claims. The two snippets provided are art-world news items from artdaily.com — one about the Towner gallery appointing Martin Clark as CEO, and one a personal essay about custom Blythe dolls. Neither mentions Teva, pregabalin, pharmaceuticals, or any related commercial entity. There is therefore no sourced basis in this dossier for founding details, headquarters, ownership, product portfolio, regulatory approvals, market availability or corporate history. Because the subject cannot be verified from the supplied material, this entry is deliberately kept short and flagged for review. It should not be treated as a confirmed brand record until authoritative sources — such as Teva corporate or regulatory filings, product labelling, or a medicines registry — are attached. Any future enrichment should confirm the exact trademark form, the jurisdictions where the product is marketed, the dosage forms and strengths, and the relationship to the parent company's generics portfolio.

No verifiable brand history can be written for Teva-Pregabalin from the supplied evidence. The two source snippets are unrelated art-world articles from artdaily.com: one reports the appointment of Martin Clark as CEO and Director of Towner in Eastbourne, and the other is a personal essay about custom Blythe dolls. Neither contains information about Teva, pregabalin, generic medicines, or any pharmaceutical brand. What can be said without fabrication is limited to the structure of the name itself: it follows the common generic-pharmaceutical convention of pairing a manufacturer's name with an international nonproprietary name, which would place it in the prescription generics category if confirmed. Confirmation of the trademark, the marketing authorisations, the launch dates and the owning legal entity would require regulatory or corporate sources that were not provided. The entry is therefore flagged for review and should be re-researched before being used as a brand record.

• 2026

  Teva Canada recalls two lots of Teva-Pregabalin 150 mg capsules due to sertraline cross-contamination

  Teva Canada Ltd. recalled two lots of Teva-Pregabalin 150 mg capsules (DIN 02361205, lots 100070495 and 100068913, expiry July 31, 2027) after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis. Health Canada is monitoring the company's recall and implementation of corrective and preventive actions.

  Source

Read more

1. 1Towner appoints Martin Clark as new CEO & Directorartdaily.com
2. 2This Is Blythe Reviews: A Skeptical Artist's Storyartdaily.com
3. 3Teva Canada recalls two lots of Teva-Pregabalin 150 mg capsules due to sertraline cross-contaminationleaderpost.com